Sugi Predict

Sugi Predict / Compounds / SCHEMBL3374696

SCHEMBL3374696

SCHEMBL3374696

Cn1cc(Br)cc(C(=O)O)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAP2K1 Q02750 4/20 0.45
▸ AKR1C3 P42330 2/20 0.41
▸ AKR1C2 P52895 2/20 0.41
▸ AKR1C1 Q04828 2/20 0.41
▸ AKR1C4 P17516 1/20 0.41
▸ MYC P01106 1/20 0.41
▸ NR4A1 P22736 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ GLA P06280 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GRIN1 Q05586 1/20 0.37
▸ GRIN2A Q12879 1/20 0.37
▸ GRIN2B Q13224 1/20 0.37
▸ GRIN2C Q14957 1/20 0.37
▸ GPR35 Q9HC97 1/20 0.37
▸ BRD4 O60885 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18584991 0.83 MAP2K1 (0.46) MAP2K1KDM4EMEN1RAB9AKMT2A
SCHEMBL2710900 0.80 BRD4 (0.51) MAP2K1HSD17B10KDM4EBRD4
SCHEMBL10290537 0.79 CNR1 (0.42) MAP2K1KDM4EMEN1RAB9AKMT2A
SCHEMBL20326799 0.78 MEN1 (0.43) MAP2K1MYCHSD17B10KDM4EMEN1
SCHEMBL23888710 0.77 MAP2K1 (0.42) MAP2K1HSD17B10KDM4EMEN1RAB9A
SCHEMBL2736516 0.77 MAP2K1 (0.40) MAP2K1HSD17B10KDM4EMEN1RAB9A
SCHEMBL2975718 0.77 KMT2A (0.60) MAP2K1AKR1C3AKR1C2AKR1C1AKR1C4
SCHEMBL19768916 0.77 CNR1 (0.43) AKR1C3AKR1C2AKR1C1AKR1C4MYC
SCHEMBL4774279 0.76 KDM4E (0.48) HSD17B10KDM4EMEN1RAB9AKMT2A
SCHEMBL3447226 0.75 SCN9A (0.40) MAP2K1MYCMEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE INCYTE CORP (US) 2025-10-23 — — US disclosed
EP-3762392-B1 THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO LTD (KR) 2024-05-15 — — EP disclosed
CN-110582493-B Benzoxazole derivatives as immunomodulators 因赛特公司 2024-03-08 — — CN disclosed
US-11787793-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-10-17 — — US disclosed
US-11787793-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-10-17 — — US disclosed
US-11787793-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-10-17 — — US disclosed
EP-4223369-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE Incyte Corporation (US) 2023-08-09 — — EP disclosed
EP-4223369-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE Incyte Corporation (US) 2023-08-09 — — EP disclosed
US-11718605-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-08-08 — — US disclosed
US-11718605-B2 Heterocyclic compounds as immunomodulators INCYTE CORPORATION (US) 2023-08-08 — — US disclosed
WO-2018119224-A1 TETRAHYDRO IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS PD-L1 INTERNALIZATION INDUCERS INCYTE CORPORATION (US) 2018-06-28 — — WO disclosed
US-20180179197-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-06-28 — — US disclosed
US-20180016260-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-01-18 — — US disclosed
US-20180016260-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-01-18 — — US disclosed
US-20180016260-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2018-01-18 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 — — US disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed
WO-2010038081-A2 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-04-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD MAP2K1 4644/4885AKR1C3 942/4885AKR1C2 1195/4885
US-20250325660-A1 IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE CD274, PDCD1LG2, PDCD1 MAP2K1 4241/4885AKR1C3 4513/4885AKR1C2 4529/4885
US-11718605-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS MAP2K1 4852/4885AKR1C3 693/4885AKR1C2 1077/4885
US-11787793-B2 Heterocyclic compounds as immunomodulators CD74, IL2, ICOS MAP2K1 4852/4885AKR1C3 693/4885AKR1C2 1077/4885
US-20180179197-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS MAP2K1 4852/4885AKR1C3 693/4885AKR1C2 1077/4885
US-20180016260-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS MAP2K1 4852/4885AKR1C3 693/4885AKR1C2 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.